Sialadenopapillary Ductal Tumor: Case Series and Review of the Literature.

Head Neck PatholOct 26, 2026 (epub)

Angela C Chi, Justin A Bishop, Molly Housley Smith et al.

✦ AI-curated · Sources linked

Case in brief

The authors describe three patients with sialadenopapillary ductal tumors, a rare neoplasm of likely minor salivary gland origin characterized by prominent submucosal ductal proliferation and multilayered cystic structures with a peripheral myoepithelial layer. Two tumors arose in the posterior mandible and were treated by marginal resection; the palatal tumor was treated by simple excision. Their literature review identified 37 previously reported cases. Across the reviewed cases and current series, treatment ranged from local procedures to resection; cervical lymph node metastasis and recurrence were reported. The authors suggest these tumors may be low-grade adenocarcinomas and support long-term surveillance, while noting that evidence remains limited.

What made this case unusual

The tumor’s distinctive combination of prominent submucosal ductal proliferation and multilayered cystic structures with a peripheral myoepithelial layer helps define a rare clinicopathologic spectrum that has been reported under several different diagnostic labels.

Diagnostic / clinical pearl

Recognizing the characteristic ductal and cystic architecture can help identify sialadenopapillary ductal tumor and distinguish it from entities excluded by WHO criteria, including intraductal carcinoma, salivary duct carcinoma, and epithelial-myoepithelial carcinoma.

Why it matters

The authors consider these tumors potentially low-grade adenocarcinomas, but the evidence consists of case reports and series; further study is needed to guide evidence-based treatment.

Source

Published in Head Neck Pathol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pathology (Anatomic & Clinical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.